Bladder cancer breakthrough? drug combo aims to stop tumors returning

NCT ID NCT05327647

Recruiting now Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug bicalutamide to standard BCG therapy can help prevent bladder tumors from returning in men with non-muscle invasive bladder cancer. About 160 participants will be randomly assigned to receive either BCG alone or BCG plus bicalutamide. The main goal is to see if the combination delays or reduces cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

CHU de Québec-Université Laval
RECRUITING

Québec, Quebec, G1G 5X1, Canada
CIUSSS de l'Estrie - CHUS
RECRUITING

Sherbrooke, Quebec, J1H 5H3, Canada
Centre Hospitalier de l'Université De Montréal_CHUM
RECRUITING

Montreal, Quebec, H2X 3E4, Canada
Centre intégré de santé et services sociaux de Chaudière Appalaches
RECRUITING

Lévis, Quebec, G6V3Z1, Canada
London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5W9, Canada
McGill University Health Centre_CUSM
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
University Health Network, Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2C1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.